{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T22:39:34Z","timestamp":1784241574927,"version":"3.55.0"},"reference-count":108,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Asthma is a heterogeneous disease sharing airway instability but with different biology, risk factors, and response-to-therapy patterns. Biologics have revolutionized the one-size-fits-to-all approach to personalized medicine in severe asthma (SA), which relies on the identification of biomarkers that define distinct endotypes. Thus, blood eosinophils and, to some extent, exhaled nitric oxide (FeNO) can predict the response to approved anti-type 2 (T2) biologics (anti-IgE, anti\u2013IL-5, and anti\u2013IL-4R alpha), whereas age at onset and comorbidities such as anxiety\/depression, obesity, reflux, and upper airway disease (UAD) also influence therapeutic responses in SA. In this article, focusing on the predictive value of biomarkers for the therapeutic response to biologics in SA, we first summarize the level of prediction achieved by T2 biomarkers (blood eosinophils, FeNO) and then review whether data support the predictive value of upper airway diagnosis on such outcomes. <jats:italic>Post hoc<\/jats:italic> analysis of most studies with T2 biologics suggests that chronic rhinosinusitis with nasal polyps (CRSwNP) and, to a lower extent, allergic rhinitis may help in predicting clinical response. Considering that T2 biologics are now also approved for the treatment of severe CRSwNP, diagnosis of upper airway disease is a key step in determining eligibility for such therapy.<\/jats:p>","DOI":"10.3389\/fmed.2023.1129300","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T04:48:27Z","timestamp":1679460507000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Upper airway disease diagnosis as a predictive biomarker of therapeutic response to biologics in severe asthma"],"prefix":"10.3389","volume":"10","author":[{"given":"Sophie","family":"Cottin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Doyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Pilette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJM199912233412603","article-title":"Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group","volume":"341","author":"Milgrom","year":"1999","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1185\/030079901753403126","article-title":"Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality","volume":"17","author":"Holgate","year":"2001","journal-title":"Curr Med Res Opin."},{"key":"B3","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J Allergy Clin Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1183\/09031936.01.00092101","article-title":"The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics","volume":"18","author":"Soler","year":"2001","journal-title":"Eur Respir J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic Therapies for Severe Asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","year":"2001","journal-title":"Clin Pharmacol Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1172\/JCI84144","article-title":"Current concepts of severe asthma","volume":"126","author":"Ray","year":"2016","journal-title":"J Clin Invest."},{"key":"B8","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/all.13966","article-title":"Different endotypes and phenotypes drive the heterogeneity in severe asthma","volume":"75","author":"McDowell","year":"2020","journal-title":"Allergy."},{"key":"B9","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jaci.2021.10.035","article-title":"The Precision Interventions for Severe and\/or Exacerbation-Prone (PrecISE) Asthma Network: An overview of Network organization, procedures, and interventions","volume":"149","author":"Georas","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S2213-2600(18)30291-1","article-title":"Urgent need for pragmatic trial platforms in severe asthma","volume":"6","author":"Pilette","year":"2018","journal-title":"Lancet Respir Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.rmed.2007.01.011","article-title":"Predicting and evaluating response to omalizumab in patients with severe allergic asthma","volume":"101","author":"Bousquet","year":"2007","journal-title":"Respir Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.3390\/jpm12071093","article-title":"Eosinophilic asthma, phenotypes-endotypes and current biomarkers of choice","volume":"12","author":"Porpodis","year":"2022","journal-title":"J Pers Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jaci.2021.11.021","article-title":"Considering biomarkers in asthma disease severity","volume":"149","author":"Custovic","year":"2022","journal-title":"J Allergy Clin Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.2147\/JIR.S295038","article-title":"Recent insights into the management of inflammation in asthma","volume":"14","author":"Rupani","year":"2021","journal-title":"J Inflamm Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.jaip.2020.09.051","article-title":"The prevalence of subtypes of type 2 inflammation in an unselected population of patients with severe asthma","volume":"9","author":"Frossing","year":"2021","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/j.rmed.2014.10.007","article-title":"Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR)","volume":"108","author":"Schleich","year":"2014","journal-title":"Respir Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/0091-6749(91)90160-P","article-title":"Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness","volume":"88","author":"Bradley","year":"1991","journal-title":"J Allergy Clin Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0091-6749(99)70225-3","article-title":"Evaluation of apoptosis of eosinophils, macrophages, and T lymphocytes in mucosal biopsy specimens of patients with asthma and chronic bronchitis","volume":"103","author":"Vignola","year":"1999","journal-title":"J Allergy Clin Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1034\/j.1398-9995.2002.23608.x","article-title":"Sputum eosinophil count in a large population of patients with mild to moderate steroid-naive asthma: distribution and relationship with methacholine bronchial hyperresponsiveness","volume":"57","author":"Louis","year":"2002","journal-title":"Allergy."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1183\/09031936.00118014","article-title":"Importance of concomitant local and systemic eosinophilia in uncontrolled asthma","volume":"44","author":"Schleich","year":"2014","journal-title":"Eur Respir J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.jaip.2022.02.020","article-title":"Longitudinal Impact of Sputum Inflammatory Phenotypes on Small Airway Dysfunction and Disease Outcomes in Asthma","volume":"10","author":"Abdo","year":"2022","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0140-6736(58)91385-0","article-title":"Treatment of chronic asthma with prednisolone; significance of eosinophils in the sputum","volume":"2","author":"Brown","year":"1958","journal-title":"Lancet."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/S0140-6736(99)01813-9","article-title":"Non-eosinophilic corticosteroid unresponsive asthma","volume":"353","author":"Pavord","year":"1999","journal-title":"Lancet."},{"key":"B27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.anai.2020.04.025","article-title":"Predictive factors of response to inhaled corticosteroids in newly diagnosed asthma: A real-world observational study","volume":"125","author":"Rhyou","year":"2020","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/S0140-6736(02)11679-5","article-title":"Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial","volume":"360","author":"Green","year":"2002","journal-title":"Lancet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1183\/09031936.06.00137704","article-title":"Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations","volume":"27","author":"Jayaram","year":"2006","journal-title":"Eur Respir J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0091-6749(97)70082-4","article-title":"Measuring airway inflammation in asthma: eosinophils and eosinophilic cationic protein in induced sputum compared with peripheral blood","volume":"99","author":"Pizzichini","year":"1997","journal-title":"J Allergy Clin Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaci.2017.12.1009","article-title":"Refractory airway type 2 inflammation in a large subgroup of asthmatic patients treated with inhaled corticosteroids","volume":"143","author":"Peters","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3s","DOI":"10.1183\/09031936.02.00000302","article-title":"Sputum induction","volume":"37","author":"Paggiaro","year":"2002","journal-title":"Eur Respir J Suppl."},{"key":"B33","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1513\/AnnalsATS.201310-354OC","article-title":"Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma","volume":"11","author":"Katz","year":"2014","journal-title":"Ann Am Thorac Soc."},{"key":"B34","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1183\/23120541.00560-2021","article-title":"Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab","volume":"8","author":"Pavord","year":"2022","journal-title":"ERJ Open Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","article-title":"Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia","volume":"132","author":"Laviolette","year":"2013","journal-title":"J Allergy Clin Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"969243","DOI":"10.3389\/fmed.2022.969243","article-title":"Critical evaluation of asthma biomarkers in clinical practice","volume":"9","author":"Guida","year":"2022","journal-title":"Front Med (Lausanne)."},{"key":"B38","doi-asserted-by":"publisher","first-page":"56612","DOI":"10.3791\/56612-v","article-title":"Methodology for sputum induction and laboratory processing","volume":"130","author":"Guiot","year":"2017","journal-title":"J Vis Exp."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1164\/ajrccm.163.6.9901105","article-title":"Safety and reproducibility of sputum induction in asthmatic subjects in a multicenter study","volume":"163","author":"Fahy","year":"2001","journal-title":"Am J Respir Crit Care Med."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.042912","article-title":"Induced sputum analysis: step by step","author":"Weiszhar","year":"2013","journal-title":"Breathe."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/j.rmed.2014.08.004","article-title":"Repeatability of induced sputum measurements in moderate to severe asthma","volume":"108","author":"Rossall","year":"2014","journal-title":"Respir Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.jaip.2017.01.026","article-title":"Asthma control and sputum eosinophils: a longitudinal study in daily practice","volume":"5","author":"Demarche","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B43","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/09629350210000015692","article-title":"Induced sputum is a reproducible method to assess airway inflammation in asthma","volume":"11","author":"Bacci","year":"2002","journal-title":"Mediators Inflamm."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am J Respir Crit Care Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1513\/AnnalsATS.202010-1249OC","article-title":"A Comprehensive Analysis of the Stability of Blood Eosinophil Levels","volume":"18","author":"Chipps","year":"2021","journal-title":"Ann Am Thorac Soc."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet."},{"key":"B49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1111\/all.15197","article-title":"Baseline type 2 biomarker levels and response to tezepelumab in severe asthma","volume":"77","author":"Corren","year":"2022","journal-title":"Allergy."},{"key":"B51","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.jaci.2011.12.979","article-title":"Asthma outcomes: biomarkers","volume":"129","author":"Szefler","year":"2012","journal-title":"J Allergy Clin Immunol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e018186","DOI":"10.1136\/bmjopen-2017-018186","article-title":"Effectiveness of inhaled corticosteroids in real life on clinical outcomes, sputum cells and systemic inflammation in asthmatics: a retrospective cohort study in a secondary care centre","volume":"7","author":"Demarche","year":"2017","journal-title":"BMJ Open."},{"key":"B53","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/cea.14109","article-title":"Validation and further insight into the International Severe Asthma Registry (ISAR) eosinophil gradient algorithm in the Wessex AsThma CoHort of difficult asthma (WATCH) using historical blood eosinophil counts and induced sputum","volume":"52","author":"Barber","year":"2022","journal-title":"Clin Exp Allergy."},{"key":"B54","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1136\/thoraxjnl-2014-205634","article-title":"External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma","volume":"70","author":"Wagener","year":"2015","journal-title":"Thorax."},{"key":"B55","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/cea.12880","article-title":"Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications","volume":"47","author":"Robinson","year":"2017","journal-title":"Clin Exp Allergy."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1600965","DOI":"10.1183\/13993003.E4904-2017","article-title":"A European Respiratory Society technical standard: exhaled biomarkers in lung disease","volume":"49","author":"Horv\u00e1th","year":"2017","journal-title":"Eur Respir J."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2101585","DOI":"10.1183\/13993003.01585-2021","article-title":"European respiratory society guidelines for the diagnosis of asthma in adults","volume":"60","author":"Louis","year":"2022","journal-title":"Eur Respir J."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/S2213-2600(21)00004-7","article-title":"The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study","volume":"9","author":"McDowell","year":"2021","journal-title":"Lancet Respir Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1164\/rccm.200411-1498OC","article-title":"Exhaled nitric oxide: a predictor of steroid response","volume":"172","author":"Smith","year":"2005","journal-title":"Am J Respir Crit Care Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1164\/rccm.201204-0587OC","article-title":"The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma","volume":"186","author":"McNicholl","year":"2012","journal-title":"Am J Respir Crit Care Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jaci.2005.09.029","article-title":"Exhaled nitric oxide identifies the persistent eosinophilic phenotype in severe refractory asthma","volume":"116","author":"Silkoff","year":"2005","journal-title":"J Allergy Clin Immunol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/all.14045","article-title":"Point-of-care biomarkers in asthma management: Time to move forward","volume":"75","author":"Alving","year":"2020","journal-title":"Allergy."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1902420","DOI":"10.1183\/13993003.02420-2019","article-title":"Mepolizumab effectiveness and identification of super-responders in severe asthma","volume":"55","author":"Harvey","year":"2020","journal-title":"Eur Respir J"},{"key":"B64","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s12325-018-0702-4","article-title":"Liberty asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy\/safety in patients with uncontrolled, moderate-to-severe asthma","volume":"35","author":"Busse","year":"2018","journal-title":"Adv Ther."},{"key":"B66","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jaip.2019.08.050","article-title":"Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma","volume":"8","author":"Corren","year":"2020","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B67","doi-asserted-by":"publisher","first-page":"797","DOI":"10.4081\/mrm.2022.797","article-title":"Early effectiveness of type-2 severe asthma treatment with dupilumab in a real-life setting; a FeNO-driven choice that leads to winning management","volume":"17","author":"Carpagnano","year":"2022","journal-title":"Multidiscip Respir Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1900588","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur Respir J."},{"key":"B69","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/j.1365-2125.2011.03962.x","article-title":"Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE","volume":"72","author":"Lowe","year":"2011","journal-title":"Br J Clin Pharmacol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1067\/mai.2003.49","article-title":"Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma","volume":"111","author":"Corren","year":"2003","journal-title":"J Allergy Clin Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1378\/chest.125.4.1378","article-title":"Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma","volume":"125","author":"Bousquet","year":"2004","journal-title":"Chest."},{"key":"B74","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jaci.2006.02.046","article-title":"Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals","volume":"118","author":"Takayama","year":"2006","journal-title":"J Allergy Clin Immunol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1111\/all.13181","article-title":"Serum periostin relates to type-2 inflammation and lung function in asthma: Data from the large population-based cohort Swedish GA(2)LEN","volume":"72","author":"James","year":"2017","journal-title":"Allergy."},{"key":"B76","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/S2213-2600(15)00197-6","article-title":"Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Brightling","year":"2015","journal-title":"Lancet Respir Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1136\/thoraxjnl-2014-206719","article-title":"Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies","volume":"70","author":"Hanania","year":"2015","journal-title":"Thorax."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1056\/NEJMoa1106469","article-title":"Lebrikizumab treatment in adults with asthma","volume":"365","author":"Corren","year":"2011","journal-title":"N Engl J Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1159\/000235362","article-title":"The molecular biology of eosinophil granule proteins","volume":"94","author":"Hamann","year":"1991","journal-title":"Int Arch Allergy Appl Immunol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1034\/j.1398-9995.2000.00858.x","article-title":"Increased END\/EPX in ongoing asthma","volume":"55","author":"Morioka","year":"2000","journal-title":"Allergy."},{"key":"B81","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1016\/j.jaip.2020.03.035","article-title":"Serum eosinophil-derived neurotoxin better reflect asthma control status than blood eosinophil counts","volume":"8","author":"An","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B82","doi-asserted-by":"publisher","first-page":"394","DOI":"10.4168\/aair.2019.11.3.394","article-title":"Serum levels of eosinophil-derived neurotoxin: a biomarker for asthma severity in adult asthmatics","volume":"11","author":"Lee","year":"2019","journal-title":"Allergy Asthma Immunol Res."},{"key":"B83","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1046\/j.1365-2222.2001.01022.x","article-title":"Benefits of high altitude allergen avoidance in atopic adolescents with moderate to severe asthma, over and above treatment with high dose inhaled steroids","volume":"31","author":"Grootendorst","year":"2001","journal-title":"Clin Exp Allergy."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/S0091-6749(96)70182-3","article-title":"Urinary eosinophil protein X in children with atopic asthma: a useful marker of antiinflammatory treatment","volume":"97","author":"Kristjansson","year":"1996","journal-title":"J Allergy Clin Immunol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.rmed.2016.01.003","article-title":"Reductions in eosinophil biomarkers by benralizumab in patients with asthma","volume":"111","author":"Pham","year":"2016","journal-title":"Respir Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.3390\/biom12101385","article-title":"Galectin-10 as a Potential Biomarker for Eosinophilic Diseases","volume":"12","author":"Tomizawa","year":"2022","journal-title":"Biomolecules"},{"key":"B87","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/19458924211049867","article-title":"Chronic rhinosinusitis with nasal polyposis (CRSwNP): the correlation between expression of Galectin-10 and Clinical-Cytological Grading (CCG)","volume":"36","author":"Gelardi","year":"2022","journal-title":"Am J Rhinol Allergy."},{"key":"B88","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.5415\/apallergy.2021.11.e31","article-title":"Mepolizumab decreased the levels of serum galectin-10 and eosinophil cationic protein in asthma","volume":"11","author":"Kobayashi","year":"2021","journal-title":"Asia Pac Allergy."},{"key":"B89","doi-asserted-by":"publisher","first-page":"L548","DOI":"10.1152\/ajplung.00141.2022","article-title":"Urinary total conjugated 3-bromotyrosine, asthma severity, and exacerbation risk","volume":"323","author":"Wang","year":"2022","journal-title":"Am J Physiol Lung Cell Mol Physiol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jaci.2014.10.026","article-title":"Biomarker-based asthma phenotypes of corticosteroid response","volume":"135","author":"Cowan","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/ACI.0000000000000599","article-title":"Systemic and breath biomarkers for asthma: an update","volume":"20","author":"Mogensen","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"180056","DOI":"10.1183\/16000617.0056-2018","article-title":"Current opinions for the management of asthma associated with ear, nose and throat comorbidities","volume":"27","author":"Tiotiu","year":"2018","journal-title":"Eur Respir Rev."},{"key":"B93","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1016\/j.jaip.2019.05.009","article-title":"Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis","volume":"7","author":"Stevens","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jaci.2022.02.016","article-title":"Mechanisms and pathogenesis of chronic rhinosinusitis","volume":"149","author":"Kato","year":"2022","journal-title":"J Allergy Clin Immunol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"100469","DOI":"10.1016\/j.waojou.2020.100469","article-title":"Efficacy predictors of omalizumab in Chinese patients with moderate-to-severe allergic asthma: Findings from a post-hoc analysis of a randomised phase III study","volume":"13","author":"Li","year":"2020","journal-title":"World Allergy Organ J."},{"key":"B96","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12931-021-01746-4","article-title":"Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions","volume":"22","author":"Gibson","year":"2021","journal-title":"Respir Res."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1753466619841274","DOI":"10.1177\/1753466619841274","article-title":"Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study","volume":"13","author":"Solidoro","year":"2019","journal-title":"Ther Adv Respir Dis."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1111\/imj.13166","article-title":"Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry","volume":"46","author":"Gibson","year":"2016","journal-title":"Intern Med J."},{"key":"B99","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","article-title":"Real-world effectiveness and the characteristics of a \u201csuper-responder\u201d to mepolizumab in severe eosinophilic asthma","volume":"158","author":"Kavanagh","year":"2020","journal-title":"Chest."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.jaci.2020.02.002","article-title":"Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy","volume":"145","author":"Howarth","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.jaip.2019.09.036","article-title":"Efficacy of Intravenous Reslizumab in Oral Corticosteroid-Dependent Asthma","volume":"8","author":"Nair","year":"2020","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B102","first-page":"A1375","article-title":"Reslizumab high-responder and super-responder asthma patients","volume":"197","author":"Wechsler","year":"2018","journal-title":"Am J Respir Crit Care Med."},{"key":"B103","doi-asserted-by":"publisher","first-page":"AB86","DOI":"10.1016\/j.jaci.2015.12.409","article-title":"Efficacy of reslizumab with asthma, chronic sinusitis with nasal polyps and elevated blood eosinophils","volume":"137","author":"Weinstein","year":"2016","journal-title":"J Aller Clin Immunol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1800936","DOI":"10.1183\/13993003.00936-2018","article-title":"Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma","volume":"52","author":"Bleecker","year":"2018","journal-title":"Eur Respir J."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.jaip.2020.10.010","article-title":"Long-Term Therapy Response to Anti-IL-5 Biologics in Severe Asthma-A Real-Life Evaluation","volume":"9","author":"Eger","year":"2021","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaci.2016.05.041","article-title":"Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: A multicenter study in Europe, Asia, and Oceania","volume":"138","author":"Wang","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/j.jaci.2021.10.040","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"889221","DOI":"10.3389\/falgy.2022.889221","article-title":"White Paper on European Patient Needs and Suggestions on Chronic Type 2 Inflammation of Airways and Skin by EUFOREA","volume":"3","author":"De Prins","year":"2022","journal-title":"Front Allergy."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1129300\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T04:48:31Z","timestamp":1679460511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1129300\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,22]]},"references-count":108,"alternative-id":["10.3389\/fmed.2023.1129300"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1129300","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,22]]},"article-number":"1129300"}}